Home › Compare › CHGCY vs BTI

CHGCY vs BTI: Dividend Comparison 2026

CHGCY yields 2.99% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHGCY wins by $405.79M in total portfolio value· pulled ahead in Year 2
10 years
CHGCY
CHGCY
● Live price
2.99%
Share price
$27.52
Annual div
$0.82
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$405.82M
Annual income
$381,294,826.82
Full CHGCY calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — CHGCY vs BTI

📍 CHGCY pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHGCYBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHGCY + BTI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CHGCY pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHGCY
Annual income on $10K today (after 15% tax)
$253.82/yr
After 10yr DRIP, annual income (after tax)
$324,100,602.80/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, CHGCY beats the other by $324,098,234.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHGCY + BTI for your $10,000?

CHGCY: 50%BTI: 50%
100% BTI50/50100% CHGCY
Portfolio after 10yr
$202.93M
Annual income
$190,648,806.73/yr
Blended yield
93.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

CHGCY
No analyst data
Altman Z
22.5
Piotroski
6/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHGCY buys
0
BTI buys
0
No recent congressional trades found for CHGCY or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHGCYBTI
Forward yield2.99%5.38% ✓
Annual dividend / share$0.82$3.15 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100% ✓11.3%
Portfolio after 10y$405.82M ✓$37.7K
Annual income after 10y$381,294,826.82 ✓$2,786.64
Total dividends collected$404.01M ✓$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CHGCY vs BTI ($10,000, DRIP)

YearCHGCY PortfolioCHGCY Income/yrBTI PortfolioBTI Income/yrGap
1$11,297$597.22$11,299$598.92$2.00 → BTI
2← crossover$13,349$1,261.10$12,794$703.91+$555.00 → CHGCY
3$17,069$2,785.33$14,518$829.07+$2.6K → CHGCY
4$24,921$6,656.96$16,513$978.64+$8.4K → CHGCY
5$44,832$18,166.72$18,827$1,157.84+$26.0K → CHGCY
6$109,057$61,087.10$21,518$1,373.12+$87.5K → CHGCY
7$394,447$277,755.94$24,657$1,632.46+$369.8K → CHGCY
8$2,299,836$1,877,777.60$28,329$1,945.74+$2.27M → CHGCY
9$22,925,198$20,464,373.86$32,637$2,325.33+$22.89M → CHGCY
10$405,824,789$381,294,826.82$37,708$2,786.64+$405.79M → CHGCY

CHGCY vs BTI: Complete Analysis 2026

CHGCY — Stock

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Full CHGCY Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this CHGCY vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHGCY vs SCHDCHGCY vs JEPICHGCY vs OCHGCY vs KOCHGCY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.